Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Scotiabank
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was upgraded by equities research analysts at Scotiabank from a “sector perform” rating to a “sector outperform” rating in a report released on Monday, MarketBeat.com reports. The firm presently has a $40.00 target price on the stock. Scotiabank’s price objective would suggest a potential upside of 51.40% from […]
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was upgraded by equities research analysts at Scotiabank from a “sector perform” rating to a “sector outperform” rating in a report released on Monday, MarketBeat.com reports. The firm presently has a $40.00 target price on the stock. Scotiabank’s price objective would suggest a potential upside of 51.40% from […]
